The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase
Abstract
The multifunctional nature of Alzheimer's disease calls for MTDLs (multitarget-directed ligands) to act on different components of the pathology, like the cholinergic dysfunction and amyloid aggregation. Such MTDLs are usually on the basis of cholinesterase inhibitors (e.g. tacrine or huprine) coupled with another active molecule aimed at a different target. To aid in the design of these MTDLs, we report the crystal structures of hAChE (human acetylcholinesterase) in complex with FAS-2 (fasciculin 2) and a hydroxylated derivative of huprine (huprine W), and of hBChE (human butyrylcholinesterase) in complex with tacrine. Huprine W in hAChE and tacrine in hBChE reside in strikingly similar positions highlighting the conservation of key interactions, namely, π-π/cation-π interactions with Trp86 (Trp82), and hydrogen bonding with the main chain carbonyl of the catalytic histidine residue. Huprine W forms additional interactions with hAChE, which explains its superior affinity: the isoquinoline moiety is associated with a group of aromatic residues (Tyr337, Phe338 and Phe295 not present in hBChE) in addition to Trp86; the hydroxyl group is hydrogen bonded to both the catalytic serine residue and residues in the oxyanion hole; and the chlorine substituent is nested in a hydrophobic pocket interacting strongly with Trp439. There is no pocket in hBChE that is able to accommodate the chlorine substituent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase.
Harel, M., Schalk, I., Ehret-Sabatier, L., Bouet, F., Goeldner, M., Hirth, C., Axelsen, P. H., Silman, I., & Sussman, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.19.9031 · Cited by 899
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1035 · Cited by 891
Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products
Nicolet, Y., Lockridge, O., Masson, P., Fontecilla-Camps, J. C., & Nachon, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210241200 · Cited by 840
Self-citationGreig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734
Mesulam, M.-M., Guillozet, A., Shaw, P., Levey, A., Duysen, E. G., & Lockridge, O. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00613-3 · Cited by 650
Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site
Bourne, Y. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg005 · Cited by 488
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
Freeze-frame inhibitor captures acetylcholinesterase in a unique conformation
Bourne, Y., Kolb, H. C., Radić, Z., Sharpless, K. B., Taylor, P., & Marchot, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308206100 · Cited by 332
Kryger, G., Harel, M., Giles, K., Toker, L., Velan, B., Lazar, A., Kronman, C., Barak, D., Ariel, N., Shafferman, A., et al. (2000) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444900010659 · Cited by 310
Harel, M., Kryger, G., Rosenberry, T. L., Mallender, W. D., Lewis, T., Fletcher, R. J., Guss, J. M., Silman, I., & Sussman, J. L. (2000) · Protein Science · doi:10.1110/ps.9.6.1063 · Cited by 299
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 260
Tacrine Derivatives and Alzheimers Disease
Tumiatti, V., Minarini, A., Bolognesi, M. L., Milelli, A., Rosini, M., & Melchiorre, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111206 · Cited by 225
Targeting acetylcholinesterase to treat neurodegeneration
Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 217
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Alzheimer 100 – highlights in the history of Alzheimer research
Jellinger, K. A. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0578-3 · Cited by 159
Koellner, G., Kryger, G., Millard, C. B., Silman, I., Sussman, J. L., & Steiner, T. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3468 · Cited by 146
Brazzolotto, X., Wandhammer, M., Ronco, C., Trovaslet, M., Jean, L., Lockridge, O., Renard, P., & Nachon, F. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08672.x · Cited by 126
Self-citationDvir, H., Wong, D. M., Harel, M., Barril, X., Orozco, M., Luque, F. J., Muñoz‐Torrero, D., Camps, P., Rosenberry, T. L., Silman, I., et al. (2002) · Biochemistry · doi:10.1021/bi011652i · Cited by 125
Greenblatt, H. M., Dvir, H., Silman, I., & Sussman, J. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:369 · Cited by 112
The synaptic acetylcholinesterase tetramer assembles around a polyproline II helix
Dvir, H., Harel, M., Bon, S., Liu, W., Vidal, M., Garbay, C., Sussman, J. L., Massoulié, J., & Silman, I. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600425 · Cited by 109
Simon, S., Krejci, É., & Massoulié, J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.21.6178 · Cited by 83
Early Stages of Pathogenesis in Memory Impairment during Normal Senescence and Alzheimer's Disease
Daulatzai, M. A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1374 · Cited by 82
der Schyf, C. J. V., Gal, S., Geldenhuys, W. J., & Youdim, M. B. H. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.8.873 · Cited by 70
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer??s disease
Venneri, A., McGeown, W. J., & Shanks, M. F. (2005) · Neuroreport · doi:10.1097/00001756-200502080-00006 · Cited by 64
Marchot, P., Ravelli, R. B. G., Pras‐Raves, M. L., Bourne, Y., Vellom, D. C., Kanter, J. R., Camp, S., Sussman, J. L., & Taylor, P. (1996) · Protein Science · doi:10.1002/pro.5560050411 · Cited by 62
Ronco, C., Foucault, R., Gillon, É., Bohn, P., Nachon, F., Jean, L., & Renard, P. (2011) · ChemMedChem · doi:10.1002/cmdc.201000523 · Cited by 44
Self-citationRonco, C., Carletti, E., Colletier, J., Weik, M., Nachon, F., Jean, L., & Renard, P. (2011) · ChemMedChem · doi:10.1002/cmdc.201100438 · Cited by 42
Self-citationTreatment of Alzheimer’s disease in the long-term-care setting
Smith, D. A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070622 · Cited by 41
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease
Venneri, A., & Lane, R. M. (2009) · Neuroreport · doi:10.1097/wnr.0b013e3283207d21 · Cited by 34
Cited by
Rosenberry, T. L., Brazzolotto, X., Macdonald, I. R., Wandhammer, M., Trovaslet-Leroy, M., Darvesh, S., & Nachon, F. (2017) · Molecules · doi:10.3390/molecules22122098 · Cited by 298
Self-citationCheung, J., Gary, E. N., Shiomi, K., & Rosenberry, T. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400304w · Cited by 290
Viayna, E., Coquelle, N., Cieslikiewicz-Bouet, M., Cisternas, P., Oliva, C. A., Sánchez-López, E., Ettcheto, M., Bartolini, M., De Simone, A., Ricchini, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01775 · Cited by 106
Self-citationIdentification of Compounds for Butyrylcholinesterase Inhibition
Li, S., Li, A. J., Travers, J., Xu, T., Sakamuru, S., Klumpp-Thomas, C., Huang, R., & Xia, M. (2021) · SLAS Discovery · doi:10.1177/24725552211030897 · Cited by 60
Metadata
- Authors
- Nachon, F., Carletti, E., Ronco, C., Trovaslet, M., Nicolet, Y., Jean, L., & Renard, P.-Y.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2013-07-12
- Volume
- 453
- Issue
- 3
- Pages
- 393-399
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2104182950
- Cited by
- 478
- References
- 36
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.